 Robert MacLaren
Concepts (490)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Critical Illness | 46 | 2025 | 811 | 7.010 |
Why?
| | Intensive Care Units | 41 | 2025 | 827 | 4.970 |
Why?
| | Critical Care | 25 | 2025 | 601 | 4.710 |
Why?
| | Peptic Ulcer | 9 | 2023 | 20 | 3.940 |
Why?
| | Gastrointestinal Hemorrhage | 8 | 2024 | 132 | 3.500 |
Why?
| | Hypnotics and Sedatives | 12 | 2024 | 200 | 3.280 |
Why?
| | Pharmacy Service, Hospital | 10 | 2024 | 90 | 3.150 |
Why?
| | Histamine H2 Antagonists | 9 | 2024 | 30 | 3.000 |
Why?
| | Pharmacists | 11 | 2025 | 265 | 2.890 |
Why?
| | Proton Pump Inhibitors | 9 | 2024 | 109 | 2.870 |
Why?
| | Enteral Nutrition | 13 | 2023 | 202 | 2.840 |
Why?
| | Dexmedetomidine | 9 | 2019 | 43 | 2.690 |
Why?
| | Gastric Emptying | 8 | 2017 | 38 | 1.940 |
Why?
| | Midazolam | 4 | 2024 | 56 | 1.610 |
Why?
| | Substance Withdrawal Syndrome | 5 | 2022 | 179 | 1.550 |
Why?
| | Shock, Septic | 4 | 2022 | 219 | 1.460 |
Why?
| | Anticoagulants | 12 | 2023 | 664 | 1.390 |
Why?
| | Epoprostenol | 2 | 2023 | 136 | 1.380 |
Why?
| | Heparin | 7 | 2023 | 261 | 1.320 |
Why?
| | Professional Role | 5 | 2024 | 167 | 1.220 |
Why?
| | Metoclopramide | 7 | 2010 | 19 | 1.210 |
Why?
| | Vasopressins | 4 | 2022 | 64 | 1.140 |
Why?
| | Sepsis | 7 | 2023 | 617 | 1.080 |
Why?
| | Stress, Physiological | 5 | 2021 | 443 | 1.070 |
Why?
| | Lorazepam | 4 | 2014 | 27 | 1.070 |
Why?
| | Adult | 55 | 2025 | 37929 | 1.060 |
Why?
| | Hemorrhage | 9 | 2021 | 722 | 1.030 |
Why?
| | Pneumonia | 5 | 2022 | 639 | 1.020 |
Why?
| | Retrospective Studies | 39 | 2024 | 15657 | 1.020 |
Why?
| | Visual Acuity | 4 | 2024 | 356 | 0.980 |
Why?
| | Humans | 116 | 2025 | 137585 | 0.970 |
Why?
| | Factor VIIa | 5 | 2016 | 41 | 0.950 |
Why?
| | Thrombelastography | 2 | 2023 | 154 | 0.930 |
Why?
| | Thromboembolism | 2 | 2020 | 119 | 0.920 |
Why?
| | Vasoconstrictor Agents | 5 | 2023 | 139 | 0.920 |
Why?
| | Gastrointestinal Agents | 5 | 2010 | 65 | 0.910 |
Why?
| | Neurosurgical Procedures | 2 | 2024 | 197 | 0.900 |
Why?
| | Recombinant Proteins | 13 | 2023 | 1353 | 0.900 |
Why?
| | Proton Pumps | 2 | 2014 | 8 | 0.900 |
Why?
| | Propofol | 5 | 2019 | 73 | 0.880 |
Why?
| | Ulcer | 1 | 2023 | 33 | 0.820 |
Why?
| | Alcoholism | 2 | 2022 | 807 | 0.760 |
Why?
| | Blood Coagulation Factors | 3 | 2020 | 54 | 0.750 |
Why?
| | Hypotension | 2 | 2022 | 122 | 0.720 |
Why?
| | Hypothermia, Induced | 2 | 2013 | 80 | 0.720 |
Why?
| | Burns | 3 | 2018 | 325 | 0.720 |
Why?
| | Oseltamivir | 1 | 2021 | 12 | 0.710 |
Why?
| | Analgesia | 2 | 2018 | 94 | 0.700 |
Why?
| | Anti-Ulcer Agents | 3 | 2017 | 16 | 0.700 |
Why?
| | Rhodopsin | 1 | 2020 | 11 | 0.680 |
Why?
| | Stress, Psychological | 4 | 2024 | 1100 | 0.680 |
Why?
| | Retinal Rod Photoreceptor Cells | 1 | 2020 | 17 | 0.670 |
Why?
| | Retinal Degeneration | 1 | 2020 | 38 | 0.660 |
Why?
| | Dependovirus | 1 | 2020 | 68 | 0.650 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2022 | 234 | 0.640 |
Why?
| | Conscious Sedation | 2 | 2013 | 92 | 0.630 |
Why?
| | Venous Thromboembolism | 2 | 2021 | 316 | 0.630 |
Why?
| | Vision Tests | 1 | 2019 | 17 | 0.630 |
Why?
| | Vision, Low | 1 | 2019 | 16 | 0.620 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 2023 | 301 | 0.620 |
Why?
| | Middle Aged | 43 | 2025 | 33479 | 0.610 |
Why?
| | Esomeprazole | 1 | 2018 | 7 | 0.610 |
Why?
| | Genetic Vectors | 1 | 2020 | 319 | 0.610 |
Why?
| | Fibrinolytic Agents | 3 | 2016 | 270 | 0.600 |
Why?
| | Pulmonary Embolism | 1 | 2021 | 226 | 0.590 |
Why?
| | Fluid Therapy | 3 | 2023 | 147 | 0.580 |
Why?
| | Acute Kidney Injury | 4 | 2023 | 815 | 0.580 |
Why?
| | Genetic Therapy | 1 | 2020 | 297 | 0.580 |
Why?
| | Staphylococcal Infections | 1 | 2022 | 400 | 0.570 |
Why?
| | APACHE | 3 | 2010 | 69 | 0.570 |
Why?
| | Phenytoin | 1 | 2017 | 21 | 0.560 |
Why?
| | Erythromycin | 4 | 2010 | 25 | 0.550 |
Why?
| | Ketamine | 1 | 2018 | 94 | 0.540 |
Why?
| | Blood Coagulation Disorders | 2 | 2016 | 173 | 0.540 |
Why?
| | Albumins | 1 | 2017 | 114 | 0.530 |
Why?
| | Ethanol | 3 | 2022 | 608 | 0.530 |
Why?
| | Male | 53 | 2025 | 67762 | 0.530 |
Why?
| | Adrenergic alpha-2 Receptor Agonists | 2 | 2015 | 24 | 0.530 |
Why?
| | Plasma | 2 | 2016 | 212 | 0.520 |
Why?
| | Anticonvulsants | 2 | 2017 | 217 | 0.490 |
Why?
| | Female | 50 | 2025 | 73304 | 0.470 |
Why?
| | Blood Coagulation | 2 | 2007 | 255 | 0.470 |
Why?
| | Aged | 28 | 2024 | 23961 | 0.470 |
Why?
| | Glial Cell Line-Derived Neurotrophic Factor | 1 | 2015 | 17 | 0.470 |
Why?
| | Partial Thromboplastin Time | 4 | 2023 | 57 | 0.460 |
Why?
| | Nerve Growth Factor | 1 | 2015 | 30 | 0.460 |
Why?
| | Acetaminophen | 5 | 2010 | 268 | 0.460 |
Why?
| | Hydrocortisone | 1 | 2017 | 322 | 0.460 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 2014 | 29 | 0.460 |
Why?
| | Influenza, Human | 1 | 2021 | 622 | 0.450 |
Why?
| | Community-Acquired Infections | 2 | 2014 | 174 | 0.450 |
Why?
| | Nitric Oxide | 1 | 2020 | 915 | 0.450 |
Why?
| | Stomach Diseases | 2 | 2011 | 20 | 0.440 |
Why?
| | Epinephrine | 1 | 2015 | 139 | 0.440 |
Why?
| | Drug Monitoring | 3 | 2017 | 218 | 0.440 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2015 | 131 | 0.430 |
Why?
| | Antifibrinolytic Agents | 2 | 2007 | 51 | 0.430 |
Why?
| | Evidence-Based Medicine | 4 | 2024 | 740 | 0.430 |
Why?
| | Prospective Studies | 15 | 2025 | 7604 | 0.430 |
Why?
| | Polyvinyl Chloride | 1 | 2013 | 9 | 0.420 |
Why?
| | Erythropoietin | 2 | 2005 | 95 | 0.420 |
Why?
| | Hippocampus | 1 | 2018 | 895 | 0.410 |
Why?
| | Randomized Controlled Trials as Topic | 7 | 2023 | 1477 | 0.410 |
Why?
| | Voriconazole | 3 | 2019 | 20 | 0.410 |
Why?
| | Hemodynamics | 2 | 2019 | 1113 | 0.400 |
Why?
| | Pain | 1 | 2018 | 756 | 0.390 |
Why?
| | Sodium Chloride | 1 | 2013 | 142 | 0.390 |
Why?
| | Mental Recall | 1 | 2013 | 202 | 0.370 |
Why?
| | Cross Infection | 4 | 2008 | 256 | 0.370 |
Why?
| | Drug Resistance | 2 | 2011 | 169 | 0.370 |
Why?
| | Gastrointestinal Hormones | 1 | 2011 | 5 | 0.370 |
Why?
| | Ghrelin | 1 | 2011 | 36 | 0.360 |
Why?
| | Double-Blind Method | 7 | 2020 | 1993 | 0.360 |
Why?
| | Hirudins | 4 | 2023 | 53 | 0.360 |
Why?
| | Pseudomonas Infections | 4 | 2010 | 225 | 0.360 |
Why?
| | Heparin, Low-Molecular-Weight | 2 | 2023 | 34 | 0.360 |
Why?
| | Cisapride | 2 | 2001 | 5 | 0.350 |
Why?
| | Neuromuscular Blocking Agents | 1 | 2011 | 26 | 0.350 |
Why?
| | Cohort Studies | 8 | 2023 | 5742 | 0.350 |
Why?
| | Gastrointestinal Microbiome | 1 | 2018 | 697 | 0.340 |
Why?
| | Neuromuscular Blockade | 1 | 2011 | 31 | 0.340 |
Why?
| | Infusions, Intravenous | 6 | 2016 | 413 | 0.340 |
Why?
| | Coagulants | 2 | 2008 | 19 | 0.340 |
Why?
| | Factor VII | 2 | 2007 | 24 | 0.340 |
Why?
| | Analgesics, Non-Narcotic | 2 | 2010 | 125 | 0.330 |
Why?
| | Factor Xa | 2 | 2021 | 32 | 0.330 |
Why?
| | Pharmaceutical Vehicles | 1 | 2009 | 12 | 0.330 |
Why?
| | Tachyphylaxis | 1 | 2009 | 4 | 0.330 |
Why?
| | Propylene Glycol | 1 | 2009 | 10 | 0.330 |
Why?
| | Diabetic Retinopathy | 2 | 2024 | 189 | 0.320 |
Why?
| | Antiemetics | 3 | 2010 | 43 | 0.320 |
Why?
| | Drug Therapy, Combination | 6 | 2017 | 1066 | 0.320 |
Why?
| | Heart Arrest | 1 | 2013 | 339 | 0.320 |
Why?
| | Surveys and Questionnaires | 8 | 2020 | 5778 | 0.320 |
Why?
| | Factor Xa Inhibitors | 2 | 2023 | 172 | 0.320 |
Why?
| | Protein C | 1 | 2010 | 59 | 0.320 |
Why?
| | Treatment Outcome | 14 | 2024 | 10811 | 0.310 |
Why?
| | Mutation | 2 | 2020 | 3958 | 0.310 |
Why?
| | Extravasation of Diagnostic and Therapeutic Materials | 2 | 2023 | 20 | 0.310 |
Why?
| | Pseudomonas aeruginosa | 4 | 2010 | 352 | 0.310 |
Why?
| | Respiration, Artificial | 6 | 2019 | 645 | 0.310 |
Why?
| | International Normalized Ratio | 2 | 2016 | 47 | 0.310 |
Why?
| | Bradycardia | 3 | 2021 | 55 | 0.300 |
Why?
| | Hemofiltration | 3 | 2017 | 30 | 0.300 |
Why?
| | Attitude of Health Personnel | 2 | 2014 | 1171 | 0.290 |
Why?
| | Central Serous Chorioretinopathy | 2 | 2020 | 3 | 0.290 |
Why?
| | Lung Diseases | 2 | 2007 | 767 | 0.290 |
Why?
| | Immune System | 1 | 2009 | 177 | 0.290 |
Why?
| | Antifungal Agents | 3 | 2019 | 136 | 0.290 |
Why?
| | Drug Resistance, Multiple, Bacterial | 3 | 2005 | 78 | 0.290 |
Why?
| | Nursing Audit | 1 | 2007 | 6 | 0.280 |
Why?
| | Photochemotherapy | 2 | 2020 | 44 | 0.280 |
Why?
| | Chromatography, High Pressure Liquid | 2 | 2024 | 597 | 0.280 |
Why?
| | Forms and Records Control | 1 | 2007 | 23 | 0.280 |
Why?
| | Peptide Fragments | 3 | 2023 | 706 | 0.270 |
Why?
| | Hemostatics | 1 | 2007 | 52 | 0.270 |
Why?
| | Triazoles | 2 | 2019 | 147 | 0.270 |
Why?
| | Tandem Mass Spectrometry | 2 | 2024 | 532 | 0.260 |
Why?
| | Physicians | 2 | 2013 | 910 | 0.260 |
Why?
| | Anesthesia | 1 | 2009 | 189 | 0.260 |
Why?
| | Risk Management | 1 | 2007 | 93 | 0.260 |
Why?
| | Hydrogen-Ion Concentration | 5 | 2014 | 560 | 0.260 |
Why?
| | Dopamine Antagonists | 2 | 2008 | 27 | 0.260 |
Why?
| | Bacterial Infections | 1 | 2008 | 250 | 0.260 |
Why?
| | Glutamine | 1 | 2007 | 103 | 0.250 |
Why?
| | Clinical Pharmacy Information Systems | 1 | 2006 | 6 | 0.250 |
Why?
| | Anti-Bacterial Agents | 5 | 2022 | 1809 | 0.250 |
Why?
| | Models, Economic | 1 | 2006 | 58 | 0.250 |
Why?
| | Anesthetics | 1 | 2007 | 81 | 0.250 |
Why?
| | Respiration | 1 | 2007 | 199 | 0.250 |
Why?
| | Factor VII Deficiency | 1 | 2005 | 3 | 0.240 |
Why?
| | Fentanyl | 3 | 2018 | 94 | 0.240 |
Why?
| | Practice Patterns, Physicians' | 1 | 2014 | 1313 | 0.240 |
Why?
| | Intubation, Gastrointestinal | 2 | 2008 | 79 | 0.240 |
Why?
| | Common Data Elements | 1 | 2025 | 14 | 0.230 |
Why?
| | Analgesics, Opioid | 3 | 2018 | 1000 | 0.230 |
Why?
| | Aged, 80 and over | 9 | 2024 | 7635 | 0.230 |
Why?
| | Risk Factors | 9 | 2023 | 10388 | 0.230 |
Why?
| | Intravitreal Injections | 1 | 2024 | 56 | 0.220 |
Why?
| | Macular Edema | 1 | 2024 | 43 | 0.220 |
Why?
| | Antidotes | 2 | 2016 | 143 | 0.210 |
Why?
| | Drug Interactions | 2 | 2023 | 410 | 0.210 |
Why?
| | Time Factors | 10 | 2018 | 6828 | 0.210 |
Why?
| | Regression Analysis | 3 | 2017 | 1024 | 0.210 |
Why?
| | Anemia | 1 | 2005 | 170 | 0.210 |
Why?
| | Delphi Technique | 1 | 2025 | 280 | 0.210 |
Why?
| | Clostridium Infections | 2 | 2014 | 73 | 0.200 |
Why?
| | Patients' Rooms | 1 | 2022 | 13 | 0.200 |
Why?
| | Saline Solution, Hypertonic | 1 | 2023 | 41 | 0.200 |
Why?
| | Cross-Over Studies | 3 | 2020 | 564 | 0.200 |
Why?
| | Erythrocyte Transfusion | 1 | 2005 | 194 | 0.200 |
Why?
| | Angiogenesis Inhibitors | 1 | 2024 | 229 | 0.200 |
Why?
| | Biological Availability | 1 | 2023 | 148 | 0.200 |
Why?
| | Microbial Sensitivity Tests | 3 | 2018 | 361 | 0.190 |
Why?
| | Warfarin | 2 | 2007 | 154 | 0.190 |
Why?
| | Predictive Value of Tests | 3 | 2017 | 2031 | 0.190 |
Why?
| | Renal Replacement Therapy | 2 | 2015 | 92 | 0.190 |
Why?
| | Antacids | 1 | 2001 | 16 | 0.190 |
Why?
| | United States | 8 | 2024 | 14841 | 0.190 |
Why?
| | Myocardial Infarction | 1 | 2009 | 1046 | 0.190 |
Why?
| | Minnesota | 1 | 2022 | 164 | 0.180 |
Why?
| | Colorado | 7 | 2017 | 4565 | 0.180 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2024 | 545 | 0.180 |
Why?
| | Health Care Costs | 1 | 2005 | 398 | 0.180 |
Why?
| | Anti-Infective Agents | 1 | 2004 | 255 | 0.180 |
Why?
| | Vitamin K 1 | 1 | 2001 | 3 | 0.180 |
Why?
| | Norepinephrine | 1 | 2022 | 204 | 0.180 |
Why?
| | Prothrombin | 1 | 2021 | 26 | 0.180 |
Why?
| | Stomach Ulcer | 2 | 2019 | 14 | 0.180 |
Why?
| | Disseminated Intravascular Coagulation | 1 | 2001 | 35 | 0.170 |
Why?
| | Incidence | 3 | 2022 | 2804 | 0.170 |
Why?
| | Pharmaceutical Preparations | 1 | 2023 | 179 | 0.170 |
Why?
| | Catheters | 1 | 2021 | 73 | 0.170 |
Why?
| | Statistics, Nonparametric | 3 | 2016 | 431 | 0.170 |
Why?
| | Resuscitation | 1 | 2023 | 251 | 0.170 |
Why?
| | Decision Support Techniques | 3 | 2014 | 421 | 0.170 |
Why?
| | Light Coagulation | 1 | 2020 | 8 | 0.170 |
Why?
| | Gene Knock-In Techniques | 1 | 2020 | 56 | 0.170 |
Why?
| | Inflammation | 1 | 2011 | 2837 | 0.160 |
Why?
| | Length of Stay | 4 | 2014 | 1215 | 0.160 |
Why?
| | Thrombolytic Therapy | 1 | 2021 | 142 | 0.160 |
Why?
| | Retinitis Pigmentosa | 1 | 2019 | 20 | 0.160 |
Why?
| | Area Under Curve | 3 | 2014 | 314 | 0.160 |
Why?
| | Ischemia | 1 | 2023 | 409 | 0.160 |
Why?
| | Photosensitizing Agents | 2 | 2020 | 41 | 0.160 |
Why?
| | Invasive Fungal Infections | 1 | 2019 | 11 | 0.150 |
Why?
| | Refraction, Ocular | 1 | 2019 | 37 | 0.150 |
Why?
| | Enzyme Inhibitors | 1 | 2002 | 840 | 0.150 |
Why?
| | Biometry | 1 | 2019 | 70 | 0.150 |
Why?
| | Disease Models, Animal | 2 | 2020 | 4295 | 0.150 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2014 | 2057 | 0.150 |
Why?
| | Electric Stimulation Therapy | 1 | 2019 | 81 | 0.150 |
Why?
| | Restraint, Physical | 1 | 2018 | 72 | 0.150 |
Why?
| | Adrenal Cortex Hormones | 1 | 2002 | 565 | 0.150 |
Why?
| | Patient Care | 1 | 2019 | 111 | 0.150 |
Why?
| | Burnout, Professional | 1 | 2025 | 442 | 0.140 |
Why?
| | Hospital Costs | 2 | 2009 | 117 | 0.140 |
Why?
| | United Kingdom | 1 | 2019 | 318 | 0.140 |
Why?
| | Administration, Inhalation | 1 | 2020 | 688 | 0.140 |
Why?
| | Nitriles | 1 | 2019 | 172 | 0.140 |
Why?
| | Vasoconstriction | 2 | 2023 | 202 | 0.140 |
Why?
| | Oxygen | 1 | 2023 | 931 | 0.140 |
Why?
| | Random Allocation | 1 | 2018 | 353 | 0.140 |
Why?
| | Patient Satisfaction | 1 | 2022 | 660 | 0.140 |
Why?
| | Wounds and Injuries | 1 | 2025 | 758 | 0.140 |
Why?
| | Cross-Sectional Studies | 3 | 2020 | 5472 | 0.140 |
Why?
| | Hepatorenal Syndrome | 2 | 2009 | 16 | 0.140 |
Why?
| | RNA, Bacterial | 1 | 2018 | 190 | 0.140 |
Why?
| | Vancomycin | 1 | 2018 | 84 | 0.140 |
Why?
| | Fat Emulsions, Intravenous | 1 | 1997 | 30 | 0.140 |
Why?
| | Anesthetics, Intravenous | 1 | 1997 | 47 | 0.140 |
Why?
| | Pharmacoepidemiology | 2 | 2014 | 19 | 0.140 |
Why?
| | Critical Care Nursing | 1 | 2018 | 51 | 0.140 |
Why?
| | Antibodies, Bacterial | 1 | 2018 | 146 | 0.140 |
Why?
| | Sucralfate | 1 | 2017 | 5 | 0.140 |
Why?
| | Piracetam | 1 | 2017 | 13 | 0.140 |
Why?
| | Immunity, Humoral | 1 | 2018 | 116 | 0.140 |
Why?
| | Cost-Benefit Analysis | 2 | 2014 | 591 | 0.140 |
Why?
| | Drug Compounding | 2 | 2017 | 101 | 0.130 |
Why?
| | Pneumococcal Vaccines | 1 | 2018 | 142 | 0.130 |
Why?
| | Administration, Oral | 5 | 2017 | 816 | 0.130 |
Why?
| | Intracranial Hemorrhages | 1 | 2017 | 85 | 0.130 |
Why?
| | Thiocyanates | 1 | 2016 | 31 | 0.130 |
Why?
| | Nitroprusside | 1 | 2016 | 69 | 0.130 |
Why?
| | Thiosulfates | 1 | 2016 | 19 | 0.130 |
Why?
| | Analgesics | 1 | 2018 | 206 | 0.130 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2018 | 549 | 0.130 |
Why?
| | Clinical Trials as Topic | 3 | 2009 | 1050 | 0.120 |
Why?
| | Pyridines | 1 | 2019 | 506 | 0.120 |
Why?
| | Placebo Effect | 1 | 2015 | 25 | 0.120 |
Why?
| | Therapeutics | 1 | 2015 | 14 | 0.120 |
Why?
| | Academic Medical Centers | 3 | 2019 | 512 | 0.120 |
Why?
| | Peptic Ulcer Hemorrhage | 1 | 2014 | 6 | 0.120 |
Why?
| | Respiratory Insufficiency | 1 | 1998 | 318 | 0.120 |
Why?
| | beta-Cyclodextrins | 1 | 2015 | 28 | 0.110 |
Why?
| | Methanol | 1 | 2015 | 38 | 0.110 |
Why?
| | Thrombosis | 1 | 2019 | 371 | 0.110 |
Why?
| | Antiviral Agents | 1 | 2021 | 744 | 0.110 |
Why?
| | Pain Management | 1 | 2018 | 352 | 0.110 |
Why?
| | Mice, Transgenic | 1 | 2020 | 2167 | 0.110 |
Why?
| | Multivariate Analysis | 3 | 2017 | 1509 | 0.110 |
Why?
| | Vitreoretinopathy, Proliferative | 1 | 2014 | 14 | 0.110 |
Why?
| | Treatment Failure | 2 | 2020 | 356 | 0.110 |
Why?
| | Cardiopulmonary Bypass | 1 | 2016 | 209 | 0.110 |
Why?
| | Vasodilator Agents | 1 | 2016 | 331 | 0.110 |
Why?
| | Acute Disease | 3 | 2008 | 1007 | 0.110 |
Why?
| | Shivering | 1 | 2013 | 5 | 0.110 |
Why?
| | Practice Guidelines as Topic | 4 | 2015 | 1587 | 0.110 |
Why?
| | Tomography, Optical Coherence | 3 | 2024 | 213 | 0.110 |
Why?
| | Stress Disorders, Traumatic, Acute | 1 | 2013 | 8 | 0.110 |
Why?
| | Osmotic Pressure | 1 | 2014 | 38 | 0.110 |
Why?
| | Laser Therapy | 1 | 2015 | 130 | 0.110 |
Why?
| | Immunoglobulin G | 1 | 2018 | 893 | 0.110 |
Why?
| | Gene Expression | 1 | 2018 | 1502 | 0.100 |
Why?
| | Pneumonia, Ventilator-Associated | 1 | 2014 | 53 | 0.100 |
Why?
| | Neurologic Examination | 1 | 2013 | 110 | 0.100 |
Why?
| | Medicare | 2 | 2009 | 773 | 0.100 |
Why?
| | Benzodiazepines | 1 | 2014 | 155 | 0.100 |
Why?
| | Genetic Markers | 1 | 2014 | 344 | 0.100 |
Why?
| | Hemostasis | 2 | 2019 | 82 | 0.100 |
Why?
| | Drug Storage | 1 | 2013 | 57 | 0.100 |
Why?
| | Liver Diseases | 1 | 2016 | 315 | 0.100 |
Why?
| | Thrombocytopenia | 3 | 2018 | 200 | 0.100 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2013 | 132 | 0.100 |
Why?
| | Microphthalmos | 1 | 2013 | 1 | 0.100 |
Why?
| | Drug Packaging | 1 | 2013 | 45 | 0.100 |
Why?
| | Drug Stability | 1 | 2013 | 167 | 0.100 |
Why?
| | Injections | 1 | 2013 | 183 | 0.100 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 1 | 2013 | 180 | 0.100 |
Why?
| | Lens Implantation, Intraocular | 1 | 2013 | 59 | 0.100 |
Why?
| | Health Care Surveys | 1 | 2014 | 565 | 0.100 |
Why?
| | Propensity Score | 1 | 2014 | 294 | 0.100 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 2 | 2023 | 250 | 0.090 |
Why?
| | Motilin | 1 | 2011 | 1 | 0.090 |
Why?
| | Cholecystokinin | 1 | 2011 | 12 | 0.090 |
Why?
| | Models, Genetic | 1 | 2014 | 600 | 0.090 |
Why?
| | Respiratory Aspiration | 1 | 2011 | 31 | 0.090 |
Why?
| | Phacoemulsification | 1 | 2013 | 122 | 0.090 |
Why?
| | Renal Dialysis | 1 | 2015 | 435 | 0.090 |
Why?
| | Animals | 5 | 2020 | 36940 | 0.090 |
Why?
| | Intraoperative Complications | 2 | 2013 | 138 | 0.090 |
Why?
| | Societies, Pharmaceutical | 2 | 2020 | 21 | 0.090 |
Why?
| | RNA, Messenger | 1 | 2018 | 2833 | 0.090 |
Why?
| | Adolescent | 8 | 2019 | 21513 | 0.090 |
Why?
| | Drug Resistance, Multiple | 1 | 2010 | 25 | 0.080 |
Why?
| | Drug Administration Schedule | 4 | 2018 | 786 | 0.080 |
Why?
| | Lactoferrin | 1 | 2010 | 31 | 0.080 |
Why?
| | Contraindications | 1 | 2010 | 90 | 0.080 |
Why?
| | Severity of Illness Index | 2 | 2015 | 2828 | 0.080 |
Why?
| | Hospitals, University | 2 | 2008 | 182 | 0.080 |
Why?
| | Mice, Inbred C57BL | 2 | 2018 | 5757 | 0.080 |
Why?
| | Databases, Factual | 2 | 2018 | 1357 | 0.080 |
Why?
| | Imipenem | 2 | 2010 | 18 | 0.080 |
Why?
| | Multiple Organ Failure | 1 | 2010 | 128 | 0.080 |
Why?
| | Kidney Failure, Chronic | 1 | 2015 | 570 | 0.080 |
Why?
| | Observer Variation | 1 | 2010 | 343 | 0.080 |
Why?
| | Hypoglycemia | 1 | 2013 | 445 | 0.080 |
Why?
| | Diagnostic Errors | 1 | 2010 | 170 | 0.070 |
Why?
| | Follow-Up Studies | 4 | 2024 | 5131 | 0.070 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2010 | 137 | 0.070 |
Why?
| | Patient Care Team | 1 | 2013 | 631 | 0.070 |
Why?
| | Pilot Projects | 1 | 2013 | 1710 | 0.070 |
Why?
| | Risk Assessment | 2 | 2014 | 3457 | 0.070 |
Why?
| | Data Interpretation, Statistical | 1 | 2010 | 363 | 0.070 |
Why?
| | Quality Improvement | 3 | 2020 | 1178 | 0.070 |
Why?
| | Vitamin K | 1 | 2007 | 45 | 0.070 |
Why?
| | Gene Expression Profiling | 1 | 2014 | 1774 | 0.070 |
Why?
| | Databases as Topic | 1 | 2007 | 67 | 0.070 |
Why?
| | Blood Pressure | 2 | 2004 | 1786 | 0.070 |
Why?
| | Magnesium | 1 | 2007 | 156 | 0.070 |
Why?
| | Phosphorus | 1 | 2007 | 97 | 0.070 |
Why?
| | Potassium | 1 | 2007 | 147 | 0.070 |
Why?
| | Cost Control | 1 | 2006 | 39 | 0.070 |
Why?
| | Cellulitis | 1 | 2007 | 53 | 0.060 |
Why?
| | Cerebral Hemorrhage | 1 | 2007 | 108 | 0.060 |
Why?
| | Burn Units | 1 | 2007 | 48 | 0.060 |
Why?
| | Canada | 2 | 2014 | 418 | 0.060 |
Why?
| | Biomarkers | 2 | 2015 | 4149 | 0.060 |
Why?
| | Antihypertensive Agents | 1 | 2010 | 494 | 0.060 |
Why?
| | Anxiety | 1 | 2013 | 1035 | 0.060 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2011 | 1242 | 0.060 |
Why?
| | Societies, Medical | 2 | 2020 | 820 | 0.060 |
Why?
| | Reproducibility of Results | 2 | 2014 | 3284 | 0.060 |
Why?
| | Fibrinolysis | 1 | 2007 | 146 | 0.060 |
Why?
| | Economics, Pharmaceutical | 1 | 2005 | 9 | 0.060 |
Why?
| | Pipecolic Acids | 1 | 2005 | 26 | 0.060 |
Why?
| | Kidney Diseases | 1 | 2009 | 408 | 0.060 |
Why?
| | Genetic Predisposition to Disease | 1 | 2014 | 2426 | 0.060 |
Why?
| | Arginine Vasopressin | 1 | 2005 | 44 | 0.060 |
Why?
| | Octreotide | 1 | 2005 | 26 | 0.060 |
Why?
| | Time and Motion Studies | 1 | 2025 | 25 | 0.060 |
Why?
| | Blood Component Transfusion | 1 | 2005 | 84 | 0.060 |
Why?
| | Ranibizumab | 1 | 2024 | 20 | 0.060 |
Why?
| | Costs and Cost Analysis | 1 | 2005 | 213 | 0.060 |
Why?
| | Quality-Adjusted Life Years | 1 | 2005 | 113 | 0.060 |
Why?
| | Ceftazidime | 1 | 2004 | 6 | 0.060 |
Why?
| | beta-Lactam Resistance | 1 | 2004 | 8 | 0.060 |
Why?
| | Case-Control Studies | 2 | 2014 | 3556 | 0.060 |
Why?
| | Mice | 2 | 2020 | 17787 | 0.060 |
Why?
| | Drug Substitution | 1 | 2024 | 54 | 0.060 |
Why?
| | Depression | 1 | 2013 | 1397 | 0.060 |
Why?
| | Intraocular Pressure | 2 | 2019 | 307 | 0.050 |
Why?
| | Ciprofloxacin | 1 | 2004 | 29 | 0.050 |
Why?
| | Tobramycin | 1 | 2004 | 52 | 0.050 |
Why?
| | Sentinel Surveillance | 1 | 2004 | 49 | 0.050 |
Why?
| | Urine | 1 | 2004 | 59 | 0.050 |
Why?
| | Bevacizumab | 1 | 2024 | 138 | 0.050 |
Why?
| | Wet Macular Degeneration | 1 | 2024 | 56 | 0.050 |
Why?
| | Hospitals, Teaching | 1 | 2004 | 118 | 0.050 |
Why?
| | Hospitals, Urban | 1 | 2004 | 134 | 0.050 |
Why?
| | Sex Factors | 1 | 2009 | 2071 | 0.050 |
Why?
| | Neoplasms | 1 | 2018 | 2671 | 0.050 |
Why?
| | Models, Biological | 1 | 2010 | 1783 | 0.050 |
Why?
| | Adrenal Cortex | 1 | 2002 | 29 | 0.050 |
Why?
| | Skin Diseases | 1 | 2004 | 149 | 0.050 |
Why?
| | Hospital Mortality | 1 | 2007 | 911 | 0.050 |
Why?
| | Age Factors | 1 | 2009 | 3295 | 0.050 |
Why?
| | Pneumonia, Bacterial | 1 | 2003 | 116 | 0.050 |
Why?
| | Liver Transplantation | 1 | 2009 | 871 | 0.050 |
Why?
| | Chronic Disease | 2 | 2020 | 1793 | 0.050 |
Why?
| | Consensus | 1 | 2025 | 683 | 0.050 |
Why?
| | Hypertension | 1 | 2010 | 1295 | 0.040 |
Why?
| | Young Adult | 4 | 2019 | 13209 | 0.040 |
Why?
| | Hospitals | 1 | 2006 | 691 | 0.040 |
Why?
| | Gastric Mucosa | 1 | 2000 | 55 | 0.040 |
Why?
| | Gastrointestinal Motility | 1 | 2000 | 27 | 0.040 |
Why?
| | Subretinal Fluid | 1 | 2020 | 1 | 0.040 |
Why?
| | Methadone | 1 | 2001 | 101 | 0.040 |
Why?
| | Stomach | 1 | 2000 | 110 | 0.040 |
Why?
| | Lasers, Semiconductor | 1 | 2020 | 12 | 0.040 |
Why?
| | Therapeutic Index | 1 | 2020 | 3 | 0.040 |
Why?
| | Indocyanine Green | 1 | 2020 | 24 | 0.040 |
Why?
| | Heart Rate | 1 | 2004 | 822 | 0.040 |
Why?
| | Sickness Impact Profile | 1 | 2020 | 56 | 0.040 |
Why?
| | Coloring Agents | 1 | 2020 | 87 | 0.040 |
Why?
| | Cost Savings | 1 | 2000 | 84 | 0.040 |
Why?
| | Quality of Health Care | 1 | 2025 | 642 | 0.040 |
Why?
| | Electroretinography | 1 | 2019 | 48 | 0.040 |
Why?
| | Chi-Square Distribution | 1 | 2001 | 530 | 0.040 |
Why?
| | Placebos | 1 | 2000 | 199 | 0.040 |
Why?
| | Intestinal Absorption | 1 | 2000 | 102 | 0.040 |
Why?
| | Fluorescein Angiography | 1 | 2020 | 151 | 0.040 |
Why?
| | Causality | 1 | 2019 | 126 | 0.040 |
Why?
| | Linear Models | 1 | 2001 | 849 | 0.040 |
Why?
| | Nausea | 1 | 1998 | 111 | 0.040 |
Why?
| | Child | 2 | 2017 | 21935 | 0.040 |
Why?
| | Equipment Design | 1 | 2019 | 522 | 0.040 |
Why?
| | Parenteral Nutrition, Total | 1 | 1997 | 26 | 0.040 |
Why?
| | Vomiting | 1 | 1998 | 130 | 0.040 |
Why?
| | Data Collection | 1 | 2001 | 673 | 0.030 |
Why?
| | Comparative Effectiveness Research | 1 | 2018 | 152 | 0.030 |
Why?
| | Administration, Intravenous | 1 | 2017 | 155 | 0.030 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2019 | 213 | 0.030 |
Why?
| | Quality of Life | 2 | 2020 | 2892 | 0.030 |
Why?
| | Emergency Service, Hospital | 1 | 2007 | 2069 | 0.030 |
Why?
| | Netherlands | 1 | 2015 | 88 | 0.030 |
Why?
| | Vision, Ocular | 1 | 2015 | 37 | 0.030 |
Why?
| | Diagnostic Techniques, Ophthalmological | 1 | 2015 | 40 | 0.030 |
Why?
| | Standard of Care | 1 | 2014 | 72 | 0.030 |
Why?
| | Eye Proteins | 1 | 2014 | 92 | 0.030 |
Why?
| | Clinical Protocols | 1 | 2015 | 271 | 0.030 |
Why?
| | Crohn Disease | 1 | 1997 | 243 | 0.030 |
Why?
| | Acidosis | 1 | 2015 | 101 | 0.030 |
Why?
| | Retinal Detachment | 1 | 2014 | 63 | 0.030 |
Why?
| | Seizures | 1 | 2017 | 426 | 0.030 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2014 | 389 | 0.030 |
Why?
| | Axial Length, Eye | 1 | 2013 | 15 | 0.030 |
Why?
| | Rats | 1 | 2001 | 5647 | 0.020 |
Why?
| | Tonometry, Ocular | 1 | 2013 | 97 | 0.020 |
Why?
| | ROC Curve | 1 | 2014 | 554 | 0.020 |
Why?
| | Logistic Models | 1 | 2017 | 2074 | 0.020 |
Why?
| | Risk | 1 | 2014 | 912 | 0.020 |
Why?
| | Recovery of Function | 1 | 2015 | 653 | 0.020 |
Why?
| | Genes, Regulator | 1 | 2010 | 37 | 0.020 |
Why?
| | Antithrombins | 1 | 2010 | 60 | 0.020 |
Why?
| | Odds Ratio | 1 | 2013 | 1070 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2010 | 345 | 0.020 |
Why?
| | Microcirculation | 1 | 2010 | 149 | 0.020 |
Why?
| | Genotype | 1 | 2014 | 1916 | 0.020 |
Why?
| | Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2009 | 44 | 0.020 |
Why?
| | Research Design | 1 | 2015 | 1139 | 0.020 |
Why?
| | Drug Utilization | 1 | 2008 | 169 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 1997 | 2691 | 0.020 |
Why?
| | Drug Costs | 1 | 2008 | 106 | 0.020 |
Why?
| | Liver Cirrhosis | 1 | 2009 | 316 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2010 | 1272 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2014 | 2189 | 0.020 |
Why?
| | Inpatients | 1 | 2010 | 500 | 0.020 |
Why?
| | Thienamycins | 1 | 2005 | 5 | 0.020 |
Why?
| | Colistin | 1 | 2005 | 9 | 0.020 |
Why?
| | Polymyxin B | 1 | 2005 | 20 | 0.020 |
Why?
| | Antidiuretic Agents | 1 | 2005 | 6 | 0.020 |
Why?
| | Platelet Activation | 1 | 2005 | 93 | 0.010 |
Why?
| | Platelet Aggregation | 1 | 2005 | 103 | 0.010 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2004 | 63 | 0.010 |
Why?
| | Endothelial Cells | 1 | 2010 | 785 | 0.010 |
Why?
| | Hospitalization | 1 | 2014 | 2199 | 0.010 |
Why?
| | Arginine | 1 | 2005 | 271 | 0.010 |
Why?
| | Guideline Adherence | 1 | 2008 | 556 | 0.010 |
Why?
| | DNA | 1 | 2010 | 1459 | 0.010 |
Why?
| | Drug Resistance, Microbial | 1 | 2003 | 71 | 0.010 |
Why?
| | Kidney Transplantation | 1 | 2009 | 708 | 0.010 |
Why?
| | Algorithms | 1 | 2010 | 1704 | 0.010 |
Why?
| | Cardiac Surgical Procedures | 1 | 2008 | 530 | 0.010 |
Why?
| | Transcription Factors | 1 | 2010 | 1719 | 0.010 |
Why?
| | Sulfonamides | 1 | 2005 | 513 | 0.010 |
Why?
| | Liver | 1 | 2010 | 1943 | 0.010 |
Why?
| | Population Surveillance | 1 | 2004 | 482 | 0.010 |
Why?
| | Postoperative Complications | 1 | 2013 | 2654 | 0.010 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2001 | 233 | 0.010 |
Why?
|
|
MacLaren's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|